E-LIB Suche - Ergebnisse für: Moore, Kenneth T.

1

The Importance of Assessing Drug Pharmacokinetics and Pharm..:

Moore, Kenneth T. ; Zannikos, Peter N. ; Masters, Joanna C....
The Journal of Clinical Pharmacology. 63 (2023) S2 - p. , 2023

Link: https://doi.org/10.1002/..

2

Inclusion of Obese Participants in Drug Development: Reflec..:

Shen, Jinshan ; Moore, Kenneth T. ; Shukla, Suneet...
The Journal of Clinical Pharmacology. 64 (2023) 1 - p. 13-18 , 2023

Link: https://doi.org/10.1002/..

3

The Importance of Diversity and Inclusion in Drug Developme..:

Moore, Kenneth T. ; Grundmann, Oliver ; Iwuchukwu, Otito..
The Journal of Clinical Pharmacology. 62 (2022) 12 - p. 1475-1479 , 2022

Link: https://doi.org/10.1002/..

4

The Importance of Participant Tracking When Conducting Clin..:

Moore, Kenneth T. ; Fossler Jr, Michael J. ; Younis, Islam.
The Journal of Clinical Pharmacology. 62 (2022) 12 - p. 1465-1467 , 2022

Link: https://doi.org/10.1002/..

5

Drug Lawsuit Advertisements and the Importance of Physician..:

Moore, Kenneth T. ; Pai, Sudhakar M. ; Rogge, Mark.
The Journal of Clinical Pharmacology. 62 (2022) 12 - p. 1468-1471 , 2022

Link: https://doi.org/10.1002/..

6

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Re..:

Ashton, Veronica ; Kerolus‐Georgi, Sylvia ; Moore, Kenneth T.
The Journal of Clinical Pharmacology. 61 (2021) 8 - p. 1010-1026 , 2021

Link: https://doi.org/10.1002/..

7

Response to letter regarding article "Rivaroxaban versus wa..:

Weir, Matthew R. ; Ashton, Veronica ; Moore, Kenneth T....
American Heart Journal. 223 (2020) - p. 111-112 , 2020

Link: https://doi.org/10.1016/..

8

The Pharmacology, Efficacy, and Safety of Rivaroxaban in Ob..:

Ashton, Veronica ; Mudarris, Lana ; Moore, Kenneth T.
American Journal of Cardiovascular Drugs. 21 (2020) 3 - p. 283-297 , 2020

Link: https://doi.org/10.1007/..

9

Rivaroxaban versus warfarin in patients with nonvalvular at..:

Weir, Matthew R. ; Ashton, Veronica ; Moore, Kenneth T....
American Heart Journal. 223 (2020) - p. 3-11 , 2020

Link: https://doi.org/10.1016/..

10

OpenMDAO: an open-source framework for multidisciplinary de..:

Gray, Justin S. ; Hwang, John T. ; Martins, Joaquim R. R. A...
Structural and Multidisciplinary Optimization. 59 (2019) 4 - p. 1075-1104 , 2019

Link: https://doi.org/10.1007/..

11

Monolithic Approach for Next-Generation Aircraft Design Con..:

Roy, Satadru ; Crossley, William A. ; Moore, Kenneth T...
Journal of Aircraft. 56 (2019) 4 - p. 1565-1576 , 2019

Link: https://doi.org/10.2514/..

12

Clarification of the use of rivaroxaban in renal patients:

Moore, Kenneth T.
British Journal of Haematology. 185 (2018) 2 - p. 381-382 , 2018

Link: https://doi.org/10.1111/..

13

Clarification—safety and efficacy of apixaban versus warfar..:

Moore, Kenneth T.
Pacing and Clinical Electrophysiology. 41 (2018) 7 - p. 877-877 , 2018

Link: https://doi.org/10.1111/..

14

Rivaroxaban crushed tablet suspension characteristics and r..:

Moore, Kenneth T. ; Krook, Mark A. ; Vaidyanathan, Seema...
Clinical Pharmacology in Drug Development. 3 (2014) 4 - p. 321-327 , 2014

Link: https://doi.org/10.1002/..

15

An open‐label study to estimate the effect of steady‐state ..:

Moore, Kenneth T. ; Vaidyanathan, Seema ; Natarajan, Jaya...
The Journal of Clinical Pharmacology. 54 (2014) 12 - p. 1407-1420 , 2014

Link: https://doi.org/10.1002/..